CIK 0001661998 · Non-accelerated filer<br>Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473468154
- Phone
- 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-24 | Morrison Jodie Pope CEO | Grant or award · Stock Option (Right to Buy) | +16,901 | 16,901 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Returned to the company · Stock Option (Right to Buy) | −394,445 | 0 | ||
| 2025-02-24 | Morrison Jodie Pope CEO | Grant or award · Stock Option (Right to Buy) | +394,445 | 394,445 | ||
| 2025-02-24 | Xu Diyong Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | Xu Diyong Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 | ||
| 2025-02-24 | Iwicki Mark T Director | Returned to the company · Stock Option (Right to Buy) | −37,222 | 0 | ||
| 2025-02-24 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +37,222 | 37,222 | ||
| 2025-02-24 | Iwicki Mark T Director | Returned to the company · Stock Option (Right to Buy) | −7,615 | 0 | ||
| 2025-02-24 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +7,615 | 7,615 | ||
| 2025-02-24 | Iwicki Mark T Director | Returned to the company · Stock Option (Right to Buy) | −25,534 | 0 | ||
| 2025-02-24 | Iwicki Mark T Director | Grant or award · Stock Option (Right to Buy) | +25,534 | 25,534 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Grant or award | +37,500 | 37,500 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −87,738 | 0 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +87,738 | 87,738 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −17,951 | 0 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +17,951 | 17,951 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −70,687 | 0 | ||
| 2025-02-24 | Campagna Jason Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +70,687 | 70,687 | ||
| 2025-02-24 | GRAYZEL DAVID S. Director | Returned to the company · Stock Option (Right to Buy) | −12,767 | 0 | ||
| 2025-02-24 | GRAYZEL DAVID S. Director | Grant or award · Stock Option (Right to Buy) | +12,767 | 12,767 |
Page 5 of 11 · 207 trades